ARVN
PFE
RIGLA licensing deal with some serious upside
Pfizer and Arvinas handed Rigel Pharmaceuticals the keys to VEPPANU™ (vepdegestrant), a targeted protein degradation drug in breast cancer, through an exclusive global license agreement. In plain English: Rigel gets the right to take the wheel on development, manufacturing, and commercialization worldwide.
Show me the money
The headline number is the kind of thing investors actually notice:
- $85 million in upfront and transition payments
- Up to $320 million more tied to development, regulatory, and commercial milestones
- Tiered royalties on net sales, because of course the spreadsheet needs one more complication
Why investors should care
For Pfizer, this is another move in the great pharma game of portfolio Tetris — shifting assets around so the winners get more oxygen and the leftovers get monetized. For Rigel, it’s a chance to buy into a late-stage oncology asset with real commercial potential without having to invent the whole thing from scratch.
Big picture: in biotech, one company’s “strategic partnership” is often another company’s “we’d rather not carry this solo.” If VEPPANU works, everyone gets paid; if it stalls, well, that’s why milestone checks exist.